Navigation Links
The Huntington Study Group announces first-HD study
Date:6/21/2013

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada. The trial is sponsored by Auspex Pharmaceuticals, Inc. who is developing the drug for the treatment of Huntington disease, as well as Tourette syndrome and tardive dyskinesia.

First-HD is a randomized, double blind, placebo controlled study that examines the efficacy, safety and tolerability of a formulation of the investigational drug known as SD-809 for the treatment of chorea associated with Huntington Disease. The drug has the same mechanism of action as the FDA approved drug tetrabenazine that is used to lessen chorea in people with HD, an inherited disease that affects over 30,000 people in both the United States and Canada. HD is characterized by brain cell death that usually begins between the ages of 30 to 50. This cell loss results in motor, cognitive and behavioral signs and symptoms. Chorea, which is characterized by involuntary movements, is a hallmark of the disease.

Because SD-809 is more slowly metabolized than tetrabenazine, it provides more consistent and predictable drug levels and can be given less often than tetrabenazine. With these changes, a lower overall dose of SD-809 can be administered and it may be more convenient for persons with HD. This study will test the efficacy, safety and tolerability of a formulation of SD-809 in the management of chorea symptoms in HD patients who have not previously taken tetrabenazine. Participants will be involved in this trial for approximately 4 months.

Dr. Samuel Frank, the Principal Investigator of First-HD notes that "we are excited to work with Auspex to investigate the efficacy, safety and tolerability of this interesting and innovative new treatment for Huntington disease. We have few treatment options for Huntington disease, and only one for chorea. We hope this is a step forward in addressing this large unmet need for our patients."

There is no cost to participate in First-HD. Individuals with a diagnosis of HD who are interested in participating in First-HD should visit the HSG website: http://www.huntington-study-group.org or call toll free: 1(800) 487-7671 (North America). More information regarding this trial can also be found at http://clinicaltrials.gov


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Huntingtons Disease Linked to Reduced Cancer Risk in Study
2. Researchers restore neuron function to brains damaged by Huntingtons disease
3. Reach2HD, a Phase II study in Huntingtons disease, launched
4. Device implanted in brain has therapeutic potential for Huntingtons disease
5. Proposed drug may reverse Huntingtons disease symptoms
6. Well-known author and historian reports on progress in Huntingtons therapies
7. Human model of Huntingtons disease created from skins stem cells
8. Scientists Use Stem Cells to Mimic Huntingtons Disease
9. First Huntingtons disease center established in Washington, D.C., area
10. Cell loss in the brain relates to variations in individual symptoms in Huntingtons disease
11. NIH funds UT Dallas study on cause of Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Linfield College Online and Continuing Education ... by waiving the $50 application fee for all qualified applicants from May 1–14. Students ... Waiver option when applying . , With the RN to BSN ...
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your hair ... a few days away, it’s a good opportunity to raise awareness about a common ... Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ by the time ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Wisconsin ... Lombardo, PT, DPT, MA, OCS, WCS, has been selected by the Wisconsin Physical ... The WPTA Private Practice Award is awarded annually to a member of the ...
(Date:5/4/2016)... ... , ... Mother Nature isn’t the only mom that loves the garden. Mothers ... Celebrate these women with more than just a bouquet of flowers. Give mom, or ... , Vibrant, Edible, Compact Plants from BrazelBerries: , For a gift that adds ...
(Date:5/4/2016)... ... May 04, 2016 , ... Trinity Health ... fund and implement ideas aimed at improving care and reducing readmission rates for ... our vision for Trinity Health is to drive innovation that transforms our ministry ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... 2016  While you may be familiar with watching a film or TV show in high ... or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... 2016  Specialty Silicone Fabricators is offering teachers ... a cleanroom works. The free visual aid provides ... technology. Chris Mazelin , ... SSF enthusiastically supports the Science, Technology, Engineering and ... next generation of innovators. We want to provide ...
Breaking Medicine Technology: